Medicinal Chemistry

ISSN: 2161-0444

Open Access

Are SAR tables obsolete?

10th World Congress on Medicinal Chemistry and Drug Design

June 14-15, 2018 | Barcelona, Spain

Celerino Abad-Zapatero

University of Illinois at Chicago (UIC), USA

Keynote: Med chem (Los Angeles)

Abstract :

The listing of the structures of compounds possessing biological activity (expressed as Ki, IC50 primarily) (structure-activity tables, SAR tables) for any drug discovery project is the core of any publication accross the medicinal chemistry scientific literature. It has been the standard way of reporting the progress of pharmaceutical discovery since the historical work of Erlich and coworkers in the early 1900'S. This summary was particularly important when the main variable driving drug discovery was potency. Nowadays, drug discovery teams have to examine a large number of variables simultaneously and pay a very close atention to the physicochemical properties (primarly size, polarity/hydrophobicity) of the chemical entities being pursued. Presenting and summarizing all this information in an effective manner is of the utmost importance. ‘Alternative variables combining the affinity of the ligands with relevant physico-chemical properties of the compounds have been introduced in various ways in the literature and are being cited in the literature, particularly as ligand efficiency indices. Controversy over the usage and utility of these variables to drive drug discovery is still prevalent in the community. The presentation will discuss certain formulations of ‘Ligand Efficiency Indices’ that permit the complete mapping of chemico-biological space (CBS) in efficiency planes (AltasCBS: https://www.ebi.ac.uk/chembl/ atlascbs/), which allows a direct two-dimensional representation of the information presented in the SAR tables in a graphic manner. The proposed representation permits an easy and effective understanding of the multiparameter optimization variables involved, and intuitvely suggest the most efficient strategies to optimize the drug-like properties of the compounds.

Biography :

Celerino Abad-Zapatero has completed his PhD as a Molecular Crystallographer at University of Texas at Austin and completed Postdoctoral work on virus and protein crystallography with Prof. M.G. Rossmann at Purdue University in the mid 1980s, solving the structure of the first icosahedral viruses. He worked for over 22 years at Abbott Laboratories employing and developing the tools of macromolecular crystallography for Structure-Based Drug Design (SBDD). His research is focused on the use of alternative variables, in particular ligand efficiency indices to optimize SBDD.

E-mail: [email protected]


Copyright: This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

To cite this article:

Received Date: Jan 01, 1970
Accepted Date: Jan 01, 1970
Published Date: Jan 01, 1970

arrow_upward arrow_upward